170 related articles for article (PubMed ID: 22673148)
1. Add-on aliskiren elicits stronger renoprotection than high-dose valsartan in type 2 diabetic KKAy mice that do not respond to low-dose valsartan.
Lei B; Nakano D; Fan YY; Kitada K; Hitomi H; Kobori H; Mori H; Masaki T; Nishiyama A
J Pharmacol Sci; 2012; 119(2):131-8. PubMed ID: 22673148
[TBL] [Abstract][Full Text] [Related]
2. Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats.
Pilz B; Shagdarsuren E; Wellner M; Fiebeler A; Dechend R; Gratze P; Meiners S; Feldman DL; Webb RL; Garrelds IM; Jan Danser AH; Luft FC; Müller DN
Hypertension; 2005 Sep; 46(3):569-76. PubMed ID: 16103264
[TBL] [Abstract][Full Text] [Related]
3. Aliskiren enhances the protective effects of valsartan against cardiovascular and renal injury in endothelial nitric oxide synthase-deficient mice.
Yamamoto E; Kataoka K; Dong YF; Nakamura T; Fukuda M; Tokutomi Y; Matsuba S; Nako H; Nakagata N; Kaneko T; Ogawa H; Kim-Mitsuyama S
Hypertension; 2009 Sep; 54(3):633-8. PubMed ID: 19597038
[TBL] [Abstract][Full Text] [Related]
4. Hemodynamic and hormonal changes to dual renin-angiotensin system inhibition in experimental hypertension.
Moniwa N; Varagic J; Ahmad S; VonCannon JL; Simington SW; Wang H; Groban L; Brosnihan KB; Nagata S; Kato J; Kitamura K; Gomez RA; Lopez ML; Ferrario CM
Hypertension; 2013 Feb; 61(2):417-24. PubMed ID: 23232645
[TBL] [Abstract][Full Text] [Related]
5. Aliskiren and Valsartan reduce myocardial AT1 receptor expression and limit myocardial infarct size in diabetic mice.
Ye Y; Qian J; Castillo AC; Perez-Polo JR; Birnbaum Y
Cardiovasc Drugs Ther; 2011 Dec; 25(6):505-15. PubMed ID: 21987107
[TBL] [Abstract][Full Text] [Related]
6. Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption.
Azizi M; Ménard J; Bissery A; Guyenne TT; Bura-Rivière A; Vaidyanathan S; Camisasca RP
J Am Soc Nephrol; 2004 Dec; 15(12):3126-33. PubMed ID: 15579516
[TBL] [Abstract][Full Text] [Related]
7. Restoration of the blood pressure circadian rhythm by direct renin inhibition and blockade of angiotensin II receptors in mRen2.Lewis hypertensive rats.
Moniwa N; Varagic J; Ahmad S; VonCannon JL; Ferrario CM
Ther Adv Cardiovasc Dis; 2012 Feb; 6(1):15-29. PubMed ID: 22222314
[TBL] [Abstract][Full Text] [Related]
8. Aliskiren and valsartan combination therapy for the management of hypertension.
Epstein BJ
Vasc Health Risk Manag; 2010 Sep; 6():711-22. PubMed ID: 20859542
[TBL] [Abstract][Full Text] [Related]
9. Effect of aliskiren and valsartan combination versus aliskiren monotherapy on hemostatic biomarkers in hypertensive diabetics: Aliskiren and Valsartan Impact in Diabetics pilot trial.
Serebruany VL; Pokov AN; Aradi D; Can M; DiNicolantonio J; Kipshidze N; Atar D
Am J Ther; 2014; 21(6):482-90. PubMed ID: 23698186
[TBL] [Abstract][Full Text] [Related]
10. Aliskiren improves left ventricular dysfunction and reduces cardiac dilation in Syrian cardiomyopathic hamsters.
Crespo MJ; Cangiano JL; Altieri PI; Escobales N
J Cardiovasc Pharmacol; 2012 Jun; 59(6):547-52. PubMed ID: 22370958
[TBL] [Abstract][Full Text] [Related]
11. Hormonal and hemodynamic effects of aliskiren and valsartan and their combination in sodium-replete normotensive individuals.
Azizi M; Ménard J; Bissery A; Guyene TT; Bura-Rivière A
Clin J Am Soc Nephrol; 2007 Sep; 2(5):947-55. PubMed ID: 17702736
[TBL] [Abstract][Full Text] [Related]
12. Direct renin inhibition prevents cardiac dysfunction in a diabetic mouse model: comparison with an angiotensin receptor antagonist and angiotensin-converting enzyme inhibitor.
Thomas CM; Yong QC; Seqqat R; Chandel N; Feldman DL; Baker KM; Kumar R
Clin Sci (Lond); 2013 Apr; 124(8):529-41. PubMed ID: 23116220
[TBL] [Abstract][Full Text] [Related]
13. Long-term safety, tolerability and efficacy of aliskiren in combination with valsartan in patients with hypertension: a 6-month interim analysis.
Chrysant SG; Murray AV; Hoppe UC; Dattani D; Patel S; Hsu H; Zhang J
Curr Med Res Opin; 2008 Apr; 24(4):1039-47. PubMed ID: 18307835
[TBL] [Abstract][Full Text] [Related]
14. Aliskiren, a novel, orally effective renin inhibitor, lowers blood pressure in marmosets and spontaneously hypertensive rats.
Wood JM; Schnell CR; Cumin F; Menard J; Webb RL
J Hypertens; 2005 Feb; 23(2):417-26. PubMed ID: 15662231
[TBL] [Abstract][Full Text] [Related]
15. Aldosterone breakthrough during aliskiren, valsartan, and combination (aliskiren + valsartan) therapy.
Bomback AS; Rekhtman Y; Klemmer PJ; Canetta PA; Radhakrishnan J; Appel GB
J Am Soc Hypertens; 2012; 6(5):338-45. PubMed ID: 22995802
[TBL] [Abstract][Full Text] [Related]
16. Protective effects of aliskiren and valsartan in mice with diabetic nephropathy.
Wang W; Qiu L; Howard A; Solis N; Li C; Wang X; Kopp JB; Levi M
J Renin Angiotensin Aldosterone Syst; 2014 Dec; 15(4):384-95. PubMed ID: 25031296
[TBL] [Abstract][Full Text] [Related]
17. Aliskiren reduces home blood pressure and albuminuria in patients with hypertensive nephrosclerosis.
Suzuki H; Okada K; Abe M; Maruyama N; Yoshida Y; Baba S; Takashima H; Soma M
Clin Exp Nephrol; 2013 Jun; 17(3):386-95. PubMed ID: 23135868
[TBL] [Abstract][Full Text] [Related]
18. Sacubitril/valsartan treatment has differential effects in modulating diabetic kidney disease in
Myakala K; Jones BA; Wang XX; Levi M
Am J Physiol Renal Physiol; 2021 Jun; 320(6):F1133-F1151. PubMed ID: 33870733
[TBL] [Abstract][Full Text] [Related]
19. Aliskiren reduces myocardial ischemia-reperfusion injury by a bradykinin B2 receptor- and angiotensin AT2 receptor-mediated mechanism.
Koid SS; Ziogas J; Campbell DJ
Hypertension; 2014 Apr; 63(4):768-73. PubMed ID: 24420538
[TBL] [Abstract][Full Text] [Related]
20. AT1 antagonism and renin inhibition in mice: pivotal role of targeting angiotensin II in chronic kidney disease.
Fraune C; Lange S; Krebs C; Hölzel A; Baucke J; Divac N; Schwedhelm E; Streichert T; Velden J; Garrelds IM; Danser AH; Frenay AR; van Goor H; Jankowski V; Stahl R; Nguyen G; Wenzel UO
Am J Physiol Renal Physiol; 2012 Oct; 303(7):F1037-48. PubMed ID: 22791343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]